Ethynylated Heterodinucleotide Cytostatic Drugs for a better Cancer Therapy
Our invention describes so called duplex drugs by using phosphodiester bounding as a linker between two nucleoside analogues. Their in vivo metabolism delivers a mixture of highly active antimetabolites. First experimental data demonstrate advantages of our duplex drugs compared to classical nucleoside analogues against some types of cancer cells.
Further Information: PDF
Eberhard Karls Universität Tübingen
Phone: +49 (7071) 29-72639
Contact
Dr. Rolf Hecker
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Solving the riddle of the sphingolipids in coronary artery disease
Weill Cornell Medicine investigators have uncovered a way to unleash in blood vessels the protective effects of a type of fat-related molecule known as a sphingolipid, suggesting a promising new…
Rocks with the oldest evidence yet of Earth’s magnetic field
The 3.7 billion-year-old rocks may extend the magnetic field’s age by 200 million years. Geologists at MIT and Oxford University have uncovered ancient rocks in Greenland that bear the oldest…
Decisive breakthrough for battery production
Storing and utilising energy with innovative sulphur-based cathodes. HU research team develops foundations for sustainable battery technology Electric vehicles and portable electronic devices such as laptops and mobile phones are…
